

Drug resistance profile of Klebsiella Species from clinical isolates in a tertiary care hospital

Mohammed Amer^{1*}, Humera Qudsiya Fatima Ansari²

¹Consultant Microbiologist, Department of Microbiology, Kamineni Hospital, 4-1-1227, Kingkoti, Hyderabad, Telangana INDIA.

²Professor and HOD, Department of Microbiology, Shadan Institute of Medical Sciences, Peerancheru, Hyderabad INDIA.

Email: mdamer.2007@gmail.com, drhumera88@gmail.com

Abstract

Background: Klebsiella species are widely distributed in nature occurring as commensals in intestines and saprophytes in soil and water. These are associated with wide variety of opportunistic and nosocomial infections, such as pneumonia, U.T.I, wound infections and septicemia. Increasingly, they have developed antimicrobial resistance, notably to various Cephalosporins and Carbapenems resistance is also on the rise which is of growing concern worldwide. **Objectives:** Antibiotic susceptibility pattern of Klebsiella species along with E.S.B.L production from various clinical isolates. **Material and Methods:** A total of 244 isolates of Klebsiella species were obtained from various clinical samples identified by standard laboratory procedures. Isolates were subjected to susceptibility testing against various antibiotics by disc diffusion test as per C.L.S.I guidelines. Isolates resistant to 3rd Generation Cephalosporins were tested for E.S.B.L production by using phenotypic confirmatory tests. **Results:** Of the 244 isolates, highest isolation rate was from sputum (40.5%), followed by urine (38.5%), exudate (15.5%), blood (3.27%) and pleural fluid (2.04%). The resistance rate of Klebsiella species for 3rd Generation Cephalosporins was around (45%), Gentamicin (30.3%), Cotrimoxazole (33%), Ciprofloxacin (32%), Lomefloxacin (30%) and Levofloxacin (34%). Maximum sensitivity was seen against Piperacillin-Tazobactam (65%) and Imipenem (89.2%). 37% of isolates were confirmed by phenotypic confirmatory tests as E.S.B.L producers. **Conclusion:** Regular monitoring and judicious use of antibiotics helps in preserving the effectiveness of sensitive antibiotics and controls the emergence of further resistance.

Key Word: Klebsiella Species.

Address for Correspondence

Dr. Mohammed Amer, Consultant Microbiologist, Department of Microbiology, Kamineni Hospital, 4-1-1227, Kingkoti, Hyderabad, Telangana INDIA.

Email: mdamer.2007@gmail.com

Received Date: 08/06/2018 Revised Date: 16/07/2018 Accepted Date: 13/08/2018

DOI: <https://doi.org/10.26611/1008721>

Access this article online

Quick Response Code:



Website:

www.medpulse.in

Accessed Date:
20 August 2018

INTRODUCTION

Klebsiella is ubiquitously present and these occur as commensals in intestines and saprophytes in soil and water. They are important pathogens in nosocomial infections and are leading causes of morbidity and mortality¹ and are associated with wide variety of opportunistic infections, such as pneumonia, U.T.I, wound infections and septicemia and have been well

documented in India.² They exhibit Plasmid encoded resistance to broad spectrum Cephalosporins in GNBs which has become a widespread phenomenon in clinical medicine.³ These antibiotics are inactivated by different ESBLs which have evolved by stepwise mutation of TEM/SHV type β -lactamases which result in high morbidity and mortality.⁴

MATERIAL AND METHODS

A total of 244 isolates of *Klebsiella* species were isolated from sputum, urine, blood, exudates and pleural fluid and were examined morphologically for colony characteristics on agar media and were processed and biochemical testing done. All isolates were identified as per the standard laboratory protocols.⁵ The study was undertaken during September 2013 to August 2014. Isolates were subjected to susceptibility testing against various antibiotics by Kirby Bauer disc diffusion method as per C.L.S.I 2014 guidelines.⁶ Positive control- *K. pneumoniae* ATCC 700603. Negative control- *E. coli* ATCC 25922

RESULTS

The samples processed in the lab were sputum, urine, exudates, blood and pleural fluid. Out of the 244 samples, the organisms isolated were *Klebsiella pneumoniae* (200) and *Klebsiella oxytoca* (44). From the sputum sample, 84 (34.4%) of *K. pneumoniae* and 15 (6.1%) of *K. oxytoca* isolates were grown. 67 (27.4%) and 27 (11%) of *K.*

pneumoniae and *K. oxytoca* isolates were grown in urine samples respectively. From exudates, there was a growth pattern of 35 (14.3%) and 3 (1.2%) of *K. pneumoniae* and *K. oxytoca* respectively. Only *K. pneumoniae* was isolated from blood 8 (3.27%) and pleural fluid 5 (2.04%).

Table 1: Phenotypic Methods- Screening test and Confirmatory Method

Test	Initial Screen Test	Phenotypic Confirmatory test
Test Method	Disk Diffusion	Disk Diffusion
Medium	Mueller Hinton Agar <i>K. pneumoniae</i> -	Mueller Hinton Agar
Antimicrobial concentration	Ceftriaxone-30 mcg Ceftazidime-30 mcg Aztreonam-30 mcg Cefotaxime-30 mcg	Ceftazidime-30 mcg Ceftazidime-Clavulanic acid-30/10 mcg (AND) Cefotaxime-30 mcg Cefotaxime-Clavulanic Acid-30/10 mcg
Inoculum	Standard Disk Diffusion Procedure	Standard Disk Diffusion Procedure
Incubation	35+/-2 °C; ambient air	35+/-2 °C; ambient air

Table 2: Total number of isolates screened and confirmed for E.S.B.L production

<i>Klebsiella</i> species	Screened positive			Confirmed- (Ceftazidime Ceftazidime-Clavulanic acid)
	Ceftazidime (CAZ)	Cefotaxime (CTX)	Ceftriaxone (CTR)	
<i>Klebsiella pneumonia</i> (200)	CAZ 60	CTX 84	CTR 56	54 27%
<i>Klebsiella oxytoca</i> (44)	7	6	8	5 10%



Figure 1



Figure 2

Legend

Figure1: Combined Disk method; **Figure 2:** Double Disk Synergy Test/Double Disk Diffusion confirmatory test

Table 3: Total Antibiotic Resistance Profile for *Klebsiella* species

Sl. No	Antibiotics	<i>Klebsiella pneumoniae</i> (200)	<i>KlebsiellaOxytoca</i> (44)	Total (244)
1	Levofloxacin -5 mcg	70 (35%)	32 (72%)	102 (41%)
2	Lomefloxacin-15 mcg	64 (32%)	32 (72%)	96 (39%)
3	Ciprofloxacin – 5 mcg	56 (28%)	28 (63%)	84 (34%)
4	Amikacin-30 mcg	66 (33%)	16 (36%)	82 (33%)
5	Amoxyclav-30 mcg	90 (45%)	32 (72%)	122 (50%)
6	Ceftriaxone -10 mcg	80 (40%)	24 (54%)	104 (43%)
7	Pipercillin-Tazobactam-100/10 mcg	50 (25%)	18 (40%)	68 (27%)
8	Gentamicin-10 mcg	58 (29%)	16 (36%)	74 (30%)
9	Imipenem-10 mcg	20 (10%)	15 (35%)	35 (14%)
10	Cefotaxime-30 mcg	106 (53%)	38 (86%)	144 (50%)
11	Cefoperazone-50 mcg	86 (43%)	25 (56%)	111 (45%)
12	Amoxicillin-10 mcg	90 (45%)	24 (54%)	114 (46%)

DISCUSSION

ESBL producing *Klebsiella pneumoniae* were extensively reported worldwide after it was first identified in Enterobacteriaceae isolates from India. In this study, the frequency of ESBL producing *Klebsiella* species was found to be 37%. Higher incidences of ESBL production (71.4%) amongst gram negative bacterial isolates have been reported by other workers.⁷ Lower incidence of ESBL production (22%) was seen in Parul Agarwal *et al* study 2008.⁸ The incidence of 40% and 36% ESBL production reported by Baby Padmini *et al*, 2008 and Ritu Agarwal *et al*, 2009 respectively was in concordance with the present study.^{9, 10} Isolates from sputum samples were found to be maximum 99/244 (40.5%) and among them Resistance against Ceftriaxone-60%, Cefotaxime-59%, Amoxycylav-50%, Amoxicillin-46%, Cefoperazone-45%, Levofloxacin-34%, Lomefloxacin-30%, Ciprofloxacin-32%. E.S.B.L production was 15%. This could be due to injudicious use of antibiotics in patients suffering with recurrent respiratory tract infections and on ventilators in I.C.U's. However, 89.2% sensitivity to Imipenem was observed. This advocates the use of Carbapenem antibiotics as a therapeutic alternative in the wake of increasing resistance rates observed with conventional β -lactam antibiotics.¹¹ 67% sensitivity towards Amikacin was seen. Next to Carbapenems, Aminoglycosides can be alternative to the third generation Cephalosporins for the treatment of serious infections due to E.S.B.L producing gram negative bacteria. Outbreaks of health care-associated infection caused by *K. oxytoca* have most often been associated with contamination of environmental reservoirs such as disinfectants, multi-dose vials or parenteral fluid bags, humidifiers and ventilators.¹² This suggests that hand-washing sinks in high-intensity hospital care areas may be a reservoir for *K. oxytoca* and that person-to-person transmission may also occur.

CONCLUSION

Statistical data and evidences from researchers prove that multi drug resistant bacteria are emerging worldwide which causes many public health problems and challenges to health care. Use of broad spectrum antibiotics, insufficient aseptic conditions and technique with inadequate control of infections spread has aggravated this problem. We should take immediate action to strengthen surveillance and laboratory capacity. The physicians should also promote rational use of medicines to avoid antibiotic drug resistance.

REFERENCES

1. S.J. Cryz, R. Furer and R. Germanier "Protection against fatal *Klebsiella pneumoniae* burn wound sepsis by passive transfer of anti capsular polysaccharide", *Infect. Immun.*, 1985, 45: 139-142.
2. N.B. Mathur, A. Khalib, R. Sarkar and R. K. Puri "Mortality in neonatal septicaemia with involvement of mother in management", *Ind. J. Pediatr.*, 1991,28(ii)1259-1264.
3. G.Arlet, M.J. Sanson-le-pors, G.Rouveau, O.M. Fourinier, B. Schlemmer and A. Phillippon, "Outbreak of nosocomial infections due to *Klebsiella pneumoniae* producing SHV-4-B-Lactamases", *Eur.J. Clin. Microbiol. Insect. Dis.* 1990,9:797-803
4. K.S.Meyer, C.Vran, J.A.Eagan, B.T.Berger and J.T.Rahal "Nosocomial outbreak of *Klebsiella* infection resistant to late-generation cephalosporins" *Ann.Inern.Med.*, 1993,119:153-358
5. R.Cruickshank."Medical Microbiology, 12th eds. (revised reprint) Edinburg: Churchill Livingstone.1980, 170-189.
6. CLSI Guidelines -January-2014- Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. M100-S24.
7. K V Ramana, Anand Kalaskar, Mohan Rao, Sanjeev D Rao. Aetiology and Antimicrobial Susceptibility Patterns of Lower Respiratory Tract Infections (LRTI's) in a Rural Tertiary Care Teaching Hospital at Karimnagar, South India. *American Journal of Infectious Diseases and Microbiology*, 2013, Vol. 1, No. 5, 101-105
8. Agrawal P, Ghosh AN, Kumar S, Basu B, Kapila K. Prevalence of extended-spectrum beta-lactamases among *Escherichia coli* and *Klebsiella pneumoniae* isolates in a tertiary care hospital. *Indian J Pathol Microbiol.* 2008 Jan-Mar; 51(1):139-42.
9. S Babypadmini, B Appalaraju. Extended Spectrum β -Lactamases in urinary isolation of *Escherichia coli* and *Klebsiella pneumoniae* - Prevalence and Susceptibility pattern in a Tertiary Care Hospital. *Indian Journal of Medical Microbiology*, (2004) 22 (3):172-174
10. Ritu Aggarwal, Uma Chaudhary, and Rama Sikka. Detection of Extended Spectrum β -lactamase Production Among Uropathogens. *J Lab Physicians.* 2009 Jan-Jun; 1(1): 7-10 doi: 10.4103/0974-2727.44423
11. T Menon, D Bindu, CPG Kumar, S Nalini, MA Thirunarayan. Comparison of Double Disc and Three Dimensional Methods to Screen for ESBL Producers in a Tertiary Care Hospital. April 2006 *Indian Journal of Medical Microbiology*, (2006) 24 (2):117-120.
12. Jeong SH, Kim WM, Chang CL, Kim JM, Lee K, Chong Y, et al. Neonatal intensive care unit outbreak caused by a strain of *Klebsiella oxytoca* resistant to Aztreonam due to overproduction of chromosomal β -lactamase. *J Hosp Infect.* 2001;48:281-8. <http://dx.doi.org/10.1053/jhin.2001.1018>.

Source of Support: None Declared
Conflict of Interest: None Declared